Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

obinutuzumab

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

- PMLiVE

Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer

Tecentriq in combination with Avastin significantly improved recurrence-free survival

- PMLiVE

Roche’s influenza medicine approved by EC for children

Xofluza is now the first single-dose, oral influenza medicine approved in Europe for children

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

- PMLiVE

Roche’s high-throughput monkeypox test approved for emergency use by FDA

The tests will be conducted on the company’s 6800/8800 cobas systems

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

The diagnostics platform will allow researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links